Hansa Biopharma AB
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a HNSBF research report →
About the company
Hansa Biopharma AB (publ), a biopharmaceutical company, engages in development and commercialization of treatments for patients with rare immunological conditions in Sweden, North America, and rest of Europe. The company offers Idefirix(imlifidase), which targets and cleaves all classes of immunoglobulin G (IgG) antibodies for the desensitization treatment of sensitized adult kidney transplant patients with a positive crossmatch test. It is also developing HNSA-5487, a next generation IgG-cleaving enzyme to address acute and chronic neuro-autoimmune conditions, including myasthenia gravis.
- CEO
- Renée Julie Elisabet Aguiar-Lucander
- IPO
- 2015
- Employees
- 125
- HQ
- Lund, BY, SE
Price Chart
- Market Cap
- $245.80M
- P/E
- -4.45
- P/S
- 14.87
- P/B
- -12.89
- EV/EBITDA
- -6.06
- Div Yield
- 0.00%
- Gross Margin
- 59.68%
- Op Margin
- -299.07%
- Net Margin
- -361.44%
- ROE
- 201.60%
- ROIC
- -59.99%
- Revenue
- $222.26M · 29.74%
- Net Income
- $-534,110,000 · 33.79%
- EPS
- $-6.55 · 48.99%
- Op Income
- $-517,797,000
- FCF YoY
- 18.64%
- 52W High
- $4.58
- 52W Low
- $2.73
- 50D MA
- $2.90
- 200D MA
- $3.12
- Beta
- 1.59
- Avg Volume
- 1
Get TickerSpark's AI analysis on HNSBF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our HNSBF coverage
Recent articles, reports, and earnings notes.
No research on HNSBF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate HNSBF report →Similar companies
Peers in the same neighborhood.